Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Mild Leaks: TAVR’s Silent Enemies

Courtesy of Dr. Carlos Fava.

Even though the presence of paravalvular regurgitation (PVR) has been reduced, thank to greater experience and new devices, it is still frequent and has an impact in survival (especially moderate and severe PVR).

Mild Leaks: TAVR’s Silent Enemies

Recent research has shown that mild PVR also has a negative impact. However, these data were provided by a handful of studies and a small meta-analysis.


Read also: Who Lives Longer After TAVR, Men or Women?”.


This meta-analysis included 25 studies with 21018 patients.

 

Globally, the presence of mild PVR (compared to none/trivial PVR) was associated to higher mortality (HR 1.26, 95% CI 1.11-1.43 p=<0.0001) between 6 months and 5 years. Cardiovascular mortality also was higher with mild PVR (HR 1.28, 95% CI 1.05-1.57p=0.002) between 1 and 3 years.

 

When analyzed by subgroups, PVR was also associated to high mortality.


Read also: Transcatheter Mitral Valve Replacement Devices Multiply”.


In the non-surgical or high surgical risk group, there was higher mortality (18 studies 17,002 patients HR 1.27, 95% CI 1.09-1.47 p=0.002), but that was not the case in the low or intermediate risk group (HR 1.27 95% CI 0.95-1.69 p=0.11).

 

As regards devices, balloon-expandable valves were associated with increased mortality (HR 1.41, 95% CI 1.05-1.89, p=0.002), which was not the case with self-expandable valves (HR 1.21 0.79-0.81 p=0.38).

 

Conclusion

The presence of PVR was associated with increased all-cause mortality and cardiovascular death after TAVR. TAVR in patients with mild PVR might result beneficial, but this is yet to be determined.

 

Comment

At present, this is the largest meta-analyzis to show the presence of PVR is associated with increased mortality: 26% increase in all-cause mortality (6 months to 5 years) and 28% increase in cardiovascular mortality (between 1 and 3 years).

 

This was not the case of intermediate or low risk patients and this might be because they do not present as many comorbidities, they are not as frail, and they have more myocardial reserve to tolerate volume burden.

 

These data should make us especially demanding when choosing devices. However, PVR will eventually decrease, since we will have better technology and more experience.

 

Courtesy of Dr. Carlos Fava.

 

Original title: Does mild paravalvular regurgitation post-transcatheter aortic valve implantation affect survival? A meta-analyzis.

Reference: Tomo Ando, et al. Catheter Cardiovasc Interv 2018;91:135-147


Suscríbase a nuestro newsletter semanal

Reciba resúmenes con los últimos artículos científicos

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...